ALV-100 for Weight Maintenance in Overweight Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 220 (estimated)
- Sponsor
- Alveus Therapeutics, Inc. · Industry
This trial is looking for adults who have lost weight using a treatment called semaglutide. Participants will help assess the safety and effectiveness of a new medication called ALV-100 while maintaining their current weight loss and lifestyle.
You may be able to join if
- I am an adult aged 18 to 75.
- I have a BMI of 27 or more.
- I have been on semaglutide for weight management for at least 3 months.
- I have lost at least 10% of my body weight on semaglutide.
- I have maintained my body weight for at least 3 months.
- I am willing to stick to my current diet and exercise plan.
You may not be able to join if
- I have a history of Type 1 or Type 2 diabetes.
- I have had surgery or a device for weight loss.
- My obesity is caused by a medical disorder.
- I have taken medications that may cause significant weight gain in the last 3 months.
- I have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
- I have had cancer in the last 5 years.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityA study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
Loading trial locations…